Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
CAMBRIDGE, Mass., Oct. 27, 2016 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and audio webcast on Thursday, November 3, 2016, at 8:30 a.m. Eastern Time to report recent company highlights and third quarter 2016 financial results.
To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 96812020. The webcast can be accessed under "Events and Presentations" in the Investor Center section of the company's website at www.epizyme.com.
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients. For more information, visit www.epizyme.com.
Contacts: Media: Julie DiCarlo, Epizyme, Inc. (617) 306-5823 [email protected] Investors: Monique Allaire, THRUST IR 617-895-9511 [email protected]
